88.32MMarket Cap-0.67P/E (TTM)
0.716High0.680Low433.18KVolume0.680Open0.688Pre Close303.13KTurnover0.40%Turnover RatioLossP/E (Static)126.19MShares1.95052wk High-0.55P/B76.15MFloat Cap0.58152wk Low--Dividend TTM108.80MShs Float49.005Historical High--Div YieldTTM5.26%Amplitude0.581Historical Low0.699Avg Price1Lot Size
Karyopharm Therapeutics Stock Forum
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Therapeutics (Nasdaq: KPTI)announced a change in co-primary endpoint for its Phase 3 SENTRY Trial in myelofibrosis, replacing TSS50 with Absolute Total Symptom Score (Abs-TSS) following FDA feedback. The trial's sample size will increase to approximately 350 patients, with top-line data expected in 2H 2025.
Phase 1 trial data showed pr...
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 Sentry Trial in Myelofibrosis
No comment yet